Emergent BioSolutions (EBS) to Release Quarterly Earnings on Thursday

Emergent BioSolutions (NYSE:EBSGet Rating) is scheduled to issue its quarterly earnings data after the market closes on Thursday, April 28th. Analysts expect the company to announce earnings of $0.23 per share for the quarter. Emergent BioSolutions has set its Q1 2022 guidance at EPS and its FY 2022 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Emergent BioSolutions (NYSE:EBSGet Rating) last released its quarterly earnings results on Thursday, February 24th. The biopharmaceutical company reported $4.50 EPS for the quarter, topping the Zacks’ consensus estimate of $3.89 by $0.61. The business had revenue of $723.40 million for the quarter, compared to analyst estimates of $676.90 million. Emergent BioSolutions had a return on equity of 20.99% and a net margin of 12.88%. Emergent BioSolutions’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the prior year, the company earned $3.67 EPS. On average, analysts expect Emergent BioSolutions to post $2 EPS for the current fiscal year and $6 EPS for the next fiscal year.

EBS stock opened at $40.95 on Thursday. The business’s fifty day moving average is $41.88 and its 200-day moving average is $44.31. The company has a quick ratio of 2.46, a current ratio of 3.40 and a debt-to-equity ratio of 0.50. The company has a market cap of $2.20 billion, a P/E ratio of 9.61 and a beta of 0.88. Emergent BioSolutions has a twelve month low of $29.88 and a twelve month high of $68.03.

Several analysts have issued reports on the company. Benchmark raised Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $77.00 price target on the stock in a research note on Thursday, January 20th. Cantor Fitzgerald lifted their price target on Emergent BioSolutions from $50.00 to $55.00 in a report on Thursday, January 20th. Zacks Investment Research upgraded shares of Emergent BioSolutions from a “strong sell” rating to a “hold” rating and set a $45.00 price objective for the company in a research report on Friday, February 18th. StockNews.com began coverage on shares of Emergent BioSolutions in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Wells Fargo & Company boosted their price objective on shares of Emergent BioSolutions from $37.00 to $40.00 and gave the company an “equal weight” rating in a research report on Thursday, March 10th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $58.40.

A number of hedge funds have recently modified their holdings of EBS. Millennium Management LLC boosted its holdings in Emergent BioSolutions by 40.9% in the 2nd quarter. Millennium Management LLC now owns 6,845 shares of the biopharmaceutical company’s stock worth $431,000 after buying an additional 1,987 shares during the period. Morgan Stanley raised its position in shares of Emergent BioSolutions by 109.7% during the 2nd quarter. Morgan Stanley now owns 462,531 shares of the biopharmaceutical company’s stock valued at $29,133,000 after buying an additional 241,936 shares in the last quarter. LPL Financial LLC raised its position in Emergent BioSolutions by 8.0% in the 3rd quarter. LPL Financial LLC now owns 4,541 shares of the biopharmaceutical company’s stock worth $227,000 after purchasing an additional 337 shares during the period. Nuveen Asset Management LLC raised its position in Emergent BioSolutions by 19.8% in the 4th quarter. Nuveen Asset Management LLC now owns 196,204 shares of the biopharmaceutical company’s stock worth $8,529,000 after purchasing an additional 32,366 shares during the period. Finally, Legal & General Group Plc raised its position in Emergent BioSolutions by 48.7% in the 4th quarter. Legal & General Group Plc now owns 207,207 shares of the biopharmaceutical company’s stock worth $9,008,000 after purchasing an additional 67,883 shares during the period. 85.51% of the stock is owned by institutional investors and hedge funds.

About Emergent BioSolutions (Get Rating)

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

See Also

Earnings History for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.